Abstract: There is provided an orally-administrable formulation for the controlled release or stable storage of a granulated herb, comprising a granulated herb and at least one carrier, adjuvant or excipient therefor. Preferably, the formulation is characterized in that the total in vitro dissolution time of said formulation required for release of 75% of the active ingredients available from the formulation is between about 4 and about 18 hours, as determined by the U.S.P. XXIII paddle method at a paddle speed of 150 rpm, using simulated intestinal fluid without the digestive enzymes normally found in intestinal fluid, containing 0.1% w/w sodium dodecyl sulfate (SDS), at pH 6.8, and a temperature of 37° C. A process for the preparation of such formulation is also provided.

Abstract: A method for determining the viral retentivity of an external jacket of an implantable permselective macrocapsule. Viral retentivity describes the ability of an external jacket to retard the transport of virus particles across the jacket.

Abstract: Stable dry powders which are insoluble in hot water and which contain one or more lipid-soluble vitamins an/or one or more carotenoids are formed in an aqueous dispersion containing 2 to 50% by weight of at least one protein, 1 to 30% by weight of at least one sugar, 0.2 to 20% by weight of K2HPO4, Na2HPO4 or mixtures thereof, 0.1 to 20% by weight of at least one lipoid-soluble vitamin and/or at least one carotenoid and 5 to 95% of water. This dispersion is converted into dry powder which is heated in the range of 55° C. to 1800° C.

Abstract: A method for preparing a non-fibrous porous material essentially consisting of one or more hydrophilic polymers and/or pharmaceutical medicaments comprising forming an aqueous solution, sol or gel comprising one or more hydrophilic polymers and/or pharmaceutical medicaments, freezing the solution, sol or gel and extracting the frozen water selectively using a hydrophilic organic solvent being miscible with water at a temperature below 5° C. at which temperature the solvent is not able to dissolve the frozen solutes, leaving the non-fibrous material in a solid, porous form.

Abstract: Methods are disclosed for preparing partial and complete esters of poly-&ggr;-glutamic acid, and of the cross-linking of such esters by light of predetermined wavelength. The final products of the present invention are useful in local drug delivery in depot form, for guided tissue regeneration, and for inhibition of post-surgical adhesion.

Abstract: A striped dentifrice stable to color bleeding, wherein at least one dentifrice component contains a colorant entrained in a matrix of synthetic wax particles having a melting point range as measured by DSC is between about 40° C. and about 135° C. and the peak endotherm temperature is at least about 65° C., whereby on storage no off-taste is detected in the dentifrice nor is there any observable colorant bleeding into any other dentifrice component.

Abstract: Devices and methods for enhancing the healing of wounds, especially chronic wounds (e.g., diabetic wounds), involving the use of keratinocytes are described. Keratinocytes are grown on a transplantable solid support (e.g., collagen-coated beads), and the keratinocyte-coated solid support is placed in an enclosure. The enclosure, in turn, is placed in the wound for use as an interactive wound healing promoter.

Abstract: On account of the surprisingly powerful and long-lasting effect thereof, the salts of the L-(−)-enantiomer of (endo, syn)-(−)-3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(methylethyl)-8-azoniabicyclo [3,2,1]octane are suitable as active substances for drugs administered by inhalation for respiratory tract therapy.

Abstract: The present invention relates to a process for manufacturing a pulverous preparation of a submicron-sized biologically active compound comprising the steps of dissolving a biologically active compound under elevated pressure in a compressed gas, liquid or supercritical fluid containing a surface modifier; and rapidly expanding the compressed solution thereby precipitating the dissolved compound. An alternative process comprises dissolving the biologically active compound in compressed dimethylether, which may optionally contain a surface modifier; and spraying the compressed solution into an antisolvent phase, optionally containing a surface modifier, under vacuum, atmospheric pressure or elevated pressure. An optional third step involves converting the antisolvent phase into a pulverous preparation using conventional powder processing.

Abstract: This invention is directed to a multi-vitamin and mineral supplement tailored to men and post-menopausal women, pre-menopausal women, and athletes which supplies the right amount of the right micronutrients at the right time to assure adequate intake of micronutrients needed for disease prevention and protection against nutritional losses and deficiencies due to lifestyle factors and common inadequate dietary patterns. The multi-vitamin and mineral supplement is comprised of vitamin A, vitamin C, vitamin D, vitamin E, vitamin K, vitamin B1, vitamin B2, niacinamide, vitamin B6, vitamin B12, biotin, pantothenic acid, iron, iodine, magnesium, zinc, selenium, copper, chromium, potassium, choline, lycopene, and co-enzyme Q-10.

Abstract: The invention relates to azelastine hydrochloride-containing percutaneous preparations which comprises, as base ingredients; hydrocarbon and/or beeswax, and a surfactant.

Abstract: The invention relates to a solid pharmaceutical form of administration containing a diphosphonic acid or a physiologically compatible salt thereof as the active substance, wherein the active substance is present in granulate form, optionally together with pharmaceutical adjuvants in the inner phase, and the outer phase contains a lubricant in the form of less than 5% by weight of stearic acid relative to the total weight of the form of administration.

Abstract: The first aspect of the invention relates to a method of inducing changes in the cervical mucus of a person to achieve a contraceptive effect, and wherein the method involves administering to the person an effective amount of ebrotidine sufficient to achieve a contraceptive effect. The second aspect of the invention involves a method for treating atrophic vaginitis urinary incontinence and their associated signs and symptoms, in a person, the method involves administering to the person an effective mount of an agent sufficient to treatment of atrophic vaginitis, the agent being selected from a group consisting of stimulants or antagonists, purinergic receptors, a sodium ion update agents and an anion secretion inhibitors.

Abstract: A color blending system for foundation makeup compositions. The system includes a light component consisting of a white pigment, a first red pigment, and a black pigment; a red component consisting of the white pigment, the first red pigment, a violet pigment and a second red pigment; a green component consisting of the white pigment, a first yellow pigment, a green pigment, and a second yellow pigment; and a dark component consisting of the white pigment, the first red pigment, and the black pigment. Each component may be in the form of an emulsion, powder, liquid or solid. A method of formulating a foundation makeup composition for the skin tone of an individual through use of the color blending system. A user blends a desired amount of each of two or more of the components, thus formulating a foundation makeup composition. An individual user formulates a foundation makeup composition without either professional assistance or additional electronic or other equipment.

Abstract: An antacid formulation comprises 11.0-45.0% antacid selected from a group consisting of aluminum phosphate, dihydroxy-aluminum-sodium-carbonate, dicalcium phosphate, calcium carbonate and mixtures thereof, 4.0-8.0 oil, 0.02-1.0% antioxidant and 46.0-84.5% carrier.

Abstract: A pharmaceutical composition in the form of effervescent tablets comprising an active ingredient and an effervescent blend, wherein the effervescent blend comprises an acidic component and sodium glycine carbonate as alkaline components. Preferred acid components are fumaric acid, maleic acid, and their salts. Tablets are prepared in normal thermo-hygrometric conditions and with standard tabletting equipment.

Abstract: An orally adminsterable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicyclic acid or a pharmaceutically tolerable salt or a derivative thereof.

Abstract: A flexible ocular insert device adapted for the controlled sustained release of a drug upon insertion into the upper or lower fornix of the eye. The device comprises an elongate body of a polymeric material including two end portions, wherein the body contains a pharmaceutically active ingredient, and wherein the device has a length of at least 8 mm and a maximum diameter not exceeding 1.9 mm. The device is sufficiently flexible to allow it to bend along the curvature of the eye within the upper or lower fornix upon its being positioned so that the longitudinal axis of the device is generally parallel to the transverse diameter of the eyeball, and the device does not extend onto any visible portion of the eyeball. Each of the end portions of the device is tapered towards the extremities of the device.

Abstract: An oral preparation for the prophylactic and/or therapeutic treatment of inflammation in the mucous membrane of mammalian gastrointestinal tract (especially the human stomach) caused by Hicobacter sp. (especially H. pylori) infection is described. The preparation comprises a prophylactically and/or therapeutically effective amount of at least one type of xanthophylles. The most preferred xanthophyll is astaxanthin which is soluble in oil, preferably naturally produced astaxanthin which is esterified with fatty acids. The oral preparation may further comprise carbohydrate structures, such as those which derive from the cell wall of the production alga Haematococcus sp. The preparation may also comprise a prophylactically and/or therapeutically effective amount of a water soluble antioxidant, such as ascorbic acid (vitamin C). The oral preparation is presented in a separate unit dose or in mixture with food.

Abstract: A process and compositions for disinfecting the skin, hands and mucous membrane. The compositions contain an optical brightener and exhibit intense fluorescence in the visible wavelength range on exposure to UV light and thus permit simple monitoring of the treated skin or mucous membrane surfaces for ensuring complete disinfection, but without exhibiting the disadvantages associated with the use of conventional dyes, such as discoloration of the skin and articles.